Atria Investments Inc Acquires 13,500 Shares of Kenvue Inc. (NYSE:KVUE)

Atria Investments Inc lifted its holdings in Kenvue Inc. (NYSE:KVUE) by 13.8% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 111,326 shares of the company’s stock after purchasing an additional 13,500 shares during the period. Atria Investments Inc’s holdings in Kenvue were worth $2,575,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in KVUE. BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its stake in Kenvue by 2,453.9% in the first quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 259,729 shares of the company’s stock valued at $5,574,000 after acquiring an additional 249,559 shares in the last quarter. Kingsview Wealth Management LLC acquired a new position in Kenvue during the first quarter worth $253,000. Orion Portfolio Solutions LLC increased its position in shares of Kenvue by 21.1% during the first quarter. Orion Portfolio Solutions LLC now owns 222,512 shares of the company’s stock worth $4,775,000 after purchasing an additional 38,713 shares in the last quarter. Dorsey & Whitney Trust CO LLC grew its stake in Kenvue by 64.7% during the 1st quarter. Dorsey & Whitney Trust CO LLC now owns 17,899 shares of the company’s stock valued at $384,000 after acquiring an additional 7,032 shares in the last quarter. Finally, M&G Plc acquired a new position in Kenvue during the first quarter worth $11,803,000. 97.64% of the stock is owned by hedge funds and other institutional investors.

Kenvue Trading Up 2.0 %

Shares of KVUE opened at $23.61 on Friday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. The company has a market capitalization of $45.27 billion, a PE ratio of 42.93, a price-to-earnings-growth ratio of 2.15 and a beta of 1.36. The stock has a fifty day moving average of $22.73 and a two-hundred day moving average of $20.63. Kenvue Inc. has a fifty-two week low of $17.67 and a fifty-two week high of $23.95.

Kenvue (NYSE:KVUE) last released its quarterly earnings data on Thursday, November 7th. The company reported $0.28 EPS for the quarter, topping analysts’ consensus estimates of $0.27 by $0.01. The company had revenue of $3.90 billion for the quarter, compared to the consensus estimate of $3.92 billion. Kenvue had a return on equity of 21.43% and a net margin of 6.88%. The company’s quarterly revenue was down .4% compared to the same quarter last year. During the same period last year, the business posted $0.31 EPS. As a group, analysts forecast that Kenvue Inc. will post 1.07 EPS for the current year.

Kenvue Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, November 27th. Shareholders of record on Wednesday, November 13th will be issued a $0.205 dividend. The ex-dividend date is Wednesday, November 13th. This represents a $0.82 dividend on an annualized basis and a yield of 3.47%. Kenvue’s dividend payout ratio is currently 149.09%.

Analyst Ratings Changes

Several research analysts have weighed in on KVUE shares. UBS Group increased their target price on shares of Kenvue from $20.00 to $22.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 7th. JPMorgan Chase & Co. increased their price target on shares of Kenvue from $24.00 to $25.00 and gave the company an “overweight” rating in a research note on Friday, October 11th. Jefferies Financial Group assumed coverage on shares of Kenvue in a research note on Tuesday, September 24th. They set a “buy” rating and a $27.00 price target for the company. Piper Sandler upped their price objective on shares of Kenvue from $20.00 to $21.00 and gave the stock a “neutral” rating in a research report on Monday, September 23rd. Finally, Royal Bank of Canada downgraded shares of Kenvue from an “outperform” rating to a “sector perform” rating and set a $24.00 price target for the company. in a report on Tuesday, September 24th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $22.64.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.